Welcome to our dedicated page for Indivior SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior’s filings rarely start with simple numbers—they dive straight into opioid-treatment revenues, clinical-trial minutiae, and litigation updates that can sway valuations overnight. Finding the paragraph that explains patent expiry or the table that breaks out Suboxone sales often means scrolling through hundreds of pages. Stock Titan condenses those complexities into clear takeaways, so you can grasp material events without forensic reading.
Need the latest Indivior quarterly earnings report 10-Q filing or its blockbuster annual report 10-K simplified? They’re here, updated from EDGAR in real time and paired with AI text that translates accounting language into plain English. Our engine pinpoints opioid settlement provisions, breaks down regional sales trends, and flags any Indivior 8-K material events explained within minutes of release. You’ll also find Indivior insider trading Form 4 transactions—each alert showing executive stock movements, with context from past patterns.
Curious about governance? The Indivior proxy statement executive compensation is parsed to show pay structures and performance metrics, while Indivior Form 4 insider transactions real-time dashboards highlight buying or selling before FDA milestones. Add in side-by-side comparisons, keyword search, and downloadable tables, and you have the tools to perform fast Indivior earnings report filing analysis. Whether you’re understanding Indivior SEC documents with AI for the first time or refining an existing model, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-1, and more—complete, searchable, and explained simply.
On June 30, 2025, Indivior PLC (Nasdaq/LSE: INDV) filed a Form 8-K to furnish information under Item 7.01 (Regulation FD). The company reported, via an attached press release (Exhibit 99.1), that its ordinary shares have been selected for inclusion in both the U.S. Russell 2000 and Russell 3000 indexes. The filing contains no financial statements, earnings figures, or operational updates; it strictly communicates the index-membership development. While purely informational, index inclusion typically broadens a company’s investor base and can enhance share liquidity because passive funds that track the Russell family of indexes are required to purchase constituent stocks. No additional material events, transactions, or strategic changes are disclosed in this report.
Indivior announced two significant board-related developments in this 8-K filing. Stuart A. (Tony) Kingsley has been appointed as a non-executive director effective July 1, 2025. His appointment aligns with the Amended and Restated Relationship Agreement with Oaktree Value Opportunities Fund and related entities.
The company also disclosed new director equity arrangements:
- Five U.S.-based non-executive directors (Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, and David Wheadon) entered into a Purchase Plan with J.P. Morgan Securities for quarterly stock purchases
- The plan allows directors to defer approximately 70-80% of their after-tax base retainer into company shares
- U.K.-based director Juliet Thompson and related party Timothy Thompson purchased 1,925 and 3,850 Ordinary Shares respectively, with company reimbursement planned over the next year
These arrangements demonstrate a strategic move to increase share ownership among non-executive directors, aligning with the 2025 Directors' Remuneration Policy approved by shareholders.
FAQ
What is the current stock price of Indivior (INDV)?
What is the market cap of Indivior (INDV)?
What is the core focus of Indivior PLC?
How does Indivior generate its revenue?
What distinguishes Indivior in the pharmaceutical industry?
How does Indivior ensure the safety and efficacy of its products?
What role does research and development play at Indivior?
How does Indivior maintain a competitive edge?
What impact does Indivior aim to have on public health?
